Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2Psoriasis 1Polycystic Ovary Syndrome 1Osteoarthritis 1Neoplasms 1Esophageal Neoplasms 1Cardiovascular Diseases 1Autoimmune Diseases 1Arthritis, Rheumatoid 1

Interventions

pembrolizumab 91Blood Specimen Collection 44Cyclophosphamide 37Nivolumab 36Bevacizumab 36Standard of Care 32Carboplatin 31Surveys and Questionnaires 29Paclitaxel 28atezolizumab 25Exercise 25Pemetrexed 24Gemcitabine 24Cisplatin 23Fluorouracil 22Radiotherapy 20Leucovorin 20Dexamethasone 20Oxaliplatin 19Docetaxel 19Rituximab 16Irinotecan 16Cetuximab 16dostarlimab 15Drug Therapy 15Doxorubicin 15Biopsy 15130-nm albumin-bound paclitaxel 15Prednisone 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Fatty Acids, Omega-3 × 1 year × Clear all
NCT01169259 2025-11-06

VITAL

Brigham and Women's Hospital

Phase 3 Active not recruiting
25,871 enrolled 38 charts

Cardiovascular Diseases, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡